Torcetrapib: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
m (refs)
imported>Howard C. Berkowitz
No edit summary
Line 14: Line 14:
}}
}}


Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of [[cholesteryl ester transferase protein]] (CETP). Pfizer announces its withdrawal of torcetrapib from development<ref> ulr=http://www.pfizer.com/pfizer/download/investors/financial/8k_1202_06.pdf</ref>  Although torcetrapib quickly raised HDL [[cholesterol]] in the ILLUMINATE study, patients receiving both torcetrapib and [[atorvastatin]] has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastatin.  Similar medications include [[anacetrapib]] and [[dalcetrapib]].
Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of [[cholesteryl ester transferase protein]] (CETP).  
 
Due to safety concerns, Pfizer announced its withdrawal of torcetrapib from development<ref> url=http://www.pfizer.com/pfizer/download/investors/financial/8k_1202_06.pdf</ref>  Although torcetrapib quickly raised HDL [[cholesterol]] in the ILLUMINATE study, patients receiving both torcetrapib and [[atorvastatin]] has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastatin.  Similar medications include [[anacetrapib]] and [[dalcetrapib]].


== Chemistry ==
== Chemistry ==

Revision as of 14:03, 26 November 2010

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Torcetrapib.png
torcetrapib
IUPAC name: see chemistry section
Synonyms: see below
Formula: C26H25F9N2O4

 Uses: cardiac medication

 Properties:

 Hazards: increased death and cardiac events

Mass (g/mol): CAS #:
600.47 262352-17-0


Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of cholesteryl ester transferase protein (CETP).

Due to safety concerns, Pfizer announced its withdrawal of torcetrapib from development[1] Although torcetrapib quickly raised HDL cholesterol in the ILLUMINATE study, patients receiving both torcetrapib and atorvastatin has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastatin. Similar medications include anacetrapib and dalcetrapib.

Chemistry

The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. The drug has a formula weight of 600.47 g/mol and is registered under the CAS number 262352-17-0.

References